Biogen Alzheimer's drug closer to approval with U.S. FDA staff backing, shares jump 40%

  • 11/4/2020
  • 00:00
  • 5
  • 0
  • 0
news-picture

(Reuters) - Biogen Inc has shown “exceptionally persuasive” evidence that its experimental Alzheimer’s disease drug is effective, U.S. Food and Drug Administration staff said on Wednesday, elevating its chances of a swift approval and sending company shares soaring.

كلمات ذات صلة

ذات صلة

صورة الخبر

07 الإثنين , يونيو, 2021

U.S. approval of Biogen Alzheimer's drug sends shares soaring, hailed as 'big day" for patients

  • 0
  • وكالة رويترز
صورة الخبر

12 الإثنين , يوليو, 2021

U.S. FDA narrows use of Biogen Alzheimer's drug; shares rise

  • 0
  • وكالة رويترز
صورة الخبر

26 السبت , يونيو, 2021

U.S. lawmakers to investigate approval, pricing of Alzheimer's drug from Biogen

  • 0
  • وكالة رويترز
صورة الخبر

09 الجمعة , يوليو, 2021

FDA seeks probe into its talks with Biogen before Alzheimer's drug approval

  • 0
  • وكالة رويترز

مشاركة :